News & media

Featured story
November 15, 2022

Casma Therapeutics Raises $46.0 M in Series C Funding

CAMBRIDGE, Mass., November 15, 2022 – Casma Therapeutics, Inc., a biotechnology company engaging the autophagy system to provide innovative new medicines, today announced the closing of a Series C financing round of $46.0 million. New investors participating in the round include Amgen Ventures, LLC, Astellas Venture Management, Eisai Co., Ltd., Euclidean Capital, Mirae Asset, and Ono […]

February 13, 2024
Casma Therapeutics to Present at the Keystone Symposia on Tumor Metabolism

CAMBRIDGE, Mass., February 12, 2024 – Casma Therapeutics, Inc., a biotechnology company engaging the autophagy/lysosomal system to provide innovative new medicines, today announced that Leon Murphy, Ph.D., Chief Scientific Officer, will present at the Keystone Meeting on Tumor Metabolism in Banff, Alberta, Canada, in the “Targeting Metabolism” Section. The title of Dr. Murphy’s talk is […]

January 22, 2024
Casma Therapeutics to Present at the Joint Keystone Meeting for Proximity Based Therapeutics and Targeted Protein Degradation

CAMBRIDGE, Mass., January 22, 2024 – Casma Therapeutics, Inc., a biotechnology company engaging the autophagy/lysosomal system to provide innovative new medicines, today announced that Leon Murphy, Ph.D., Chief Scientific Officer, will present at the joint Keystone Meeting for Proximity Based Therapeutics and Targeted Protein Degradation in the section of “Emerging Proximity Biology for Target Degradation.”  […]

January 31, 2023
Casma Therapeutics Announces CEO Transition

  CAMBRIDGE, Mass., January 31, 2023 – Casma Therapeutics, a biotechnology company engaging the autophagy system to provide innovative new medicines, today announced that Keith Dionne, Ph.D., has stepped down as Chief Executive Officer, effective January 13, 2023. Dr. Dionne will continue to serve on the Board of Directors. Frank Gentile, Ph.D., formerly Chief Operating Officer […]

January 30, 2023
Casma Therapeutics Announces new Nature Publication – “Structure of the lysosomal mTORC1–TFEB–Rag–Ragulator megacomplex”

In their recent Nature paper, Casma Founders Jim Hurley and Andrea Ballabio describe the cryogenic-EM structure of an MTORC1 megacomplex.  A molecular description of this massive complex is helping us understand the regulation of the TFEB transcription factor and dependence of TFEB phosphorylation on FLCN and the RagC GDP state. Read full publication here

November 15, 2022
Casma Therapeutics Raises $46.0 M in Series C Funding

CAMBRIDGE, Mass., November 15, 2022 – Casma Therapeutics, Inc., a biotechnology company engaging the autophagy system to provide innovative new medicines, today announced the closing of a Series C financing round of $46.0 million. New investors participating in the round include Amgen Ventures, LLC, Astellas Venture Management, Eisai Co., Ltd., Euclidean Capital, Mirae Asset, and Ono […]

November 8, 2022
Casma Therapeutics to Present at Stifel 2022 Healthcare Conference

CAMBRIDGE, Mass., November 8, 2022 – Casma Therapeutics, Inc., a biotechnology company engaging the autophagy system to provide innovative new medicines, today announced that Keith Dionne, Ph.D., Chief Executive Officer, will present at the Stifel 2022 Healthcare Conference on Wednesday November 16,, 2022 at 3:00pm ET in New York, NY. About Casma Therapeutics, Inc. Casma […]

May 17, 2022
Casma Therapeutics to Present at UBS 2022 Global Healthcare Conference

CAMBRIDGE, Mass., May 17, 2022 – Casma Therapeutics, Inc., a biotechnology company engaging the autophagy system to provide innovative new medicines, today announced that Keith Dionne, Ph.D., Chief Executive Officer, will present at the UBS 2022 Global Healthcare Conference on Tuesday, May 24, 2022 at 11:30 a.m. ET in New York, NY. About Casma Therapeutics […]

August 6, 2018
Casma Therapeutics Expands Executive Team with Appointment of Two Senior Vice Presidents

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Casma Therapeutics, Inc., today announced the appointment of two executives with extensive experience in drug discovery and translational medicine to further the company’s goal of leveraging the natural cellular process of autophagy to treat neurodegenerative, inflammatory and lysosomal storage disorders, among other conditions. Jeffrey Saunders, Ph.D., Casma’s new senior vice president of drug […]

September 11, 2018
Casma Therapeutics Announces Partnership with Fondazione Telethon, Founder of the Telethon Institute of Genetics and Medicine (TIGEM)

CAMBRIDGE, Mass., September 11, 2018 — Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced a research collaboration with Fondazione Telethon, founder of the Telethon Institute of Genetics and Medicine (TIGEM), to develop new therapies for lysosomal storage disorders and more common disorders such as neurodegeneration. TIGEM, an international research […]

December 6, 2018
Casma Therapeutics Licenses Technology to Advance Autophagy-Based Drug Discovery

CAMBRIDGE, Mass., Dec. 6, 2018 – Casma Therapeutics, Inc. today announced an exclusive and nonexclusive license to technology developed at The University of Texas Southwestern Medical Center that will advance the company’s drive to harness the natural cellular processes of autophagy to design powerful new medicines for a broad range of diseases.The license includes commercial rights to a […]

Page 1 of 3